Tumor necrosis factor <unk>  promotes the inflammatory response, which in turn causes many of the clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and refractory asthma.  These disorders are sometimes treated by using a<unk> . This inhibition can be achieved with a monoclonal antibody such as infliximab (Remicade) or adalimumab (Humira), or with a circulating receptor fusion protein such as etanercept (Enbrel).
Clinical trials regarding the effectiveness of these drugs on hidradenitis suppurativa are currently ongoing.  A fourth anti-TNF biologic, certolizumab pegol, is expected to receive approval for human use in the near future.
In patients with latent Mycobacterium tuberculosis infection, active tuberculosis (TB) may develop soon after the initiation of treatment with infliximab. Before prescribing the drug, physicians should screen patients for latent TB infection or disease. The anti-TNF monoclonal antibody biologics, Infliximab and adalimumab, and the fusion protein etanercept which are all currently Food and Drug Administration (FDA) approved for human use, have label warnings which state that patients should be evaluated for latent TB infection and treatment should be initiated prior to starting therapy with these medications.<unk>  or the effects of<unk>  are also inhibited by a number of natural compounds, including curcumin     (a compound present in turmeric) and catechins (in green tea).
TNF inhibitor
Proteasome inhibitor
Monoclonal antibodies
COX-2 inhibitor
Mast cell stabilizer
Histone deacetylase inhibitor
Phosphodiesterase inhibitors
Anti inflammatory medications